<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lisa Pangemanan</style></author><author><style face="normal" font="default" size="100%">Irwanto</style></author><author><style face="normal" font="default" size="100%">Margarita M. Maramis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mozart K488 Addition Can Improve Depressive-Like Behavior in Rats: In Search of Better Management</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Corticosterone</style></keyword><keyword><style  face="normal" font="default" size="100%">Depressive-like behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine</style></keyword><keyword><style  face="normal" font="default" size="100%">Hippocampus</style></keyword><keyword><style  face="normal" font="default" size="100%">Melatonin</style></keyword><keyword><style  face="normal" font="default" size="100%">Mozart</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">348-354</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Fluoxetine is one of the medications used for the treatment of depression with several benefits, but some patients have a poor response to the drug. Several studies reported the use of Mozart music (K448) as an alternative therapy for treating the condition, yet the combination of Mozart and fluoxetine remains underexplored. In light of this, this study aims to assess the impact of combined fluoxetine and Mozart (K448) therapy on depressive-like behavior and associated hormonal changes in a rodent model subjected to Chronic Unpredictable Mild Stress (CUMS) conditions.&lt;strong&gt; Materials and Methods: &lt;/strong&gt;The depression-induced animal model received one of these three specified treatments: fluoxetine (F), Mozart (M), or a combination of fluoxetine and Mozart (F+M). The depressive-like behavior was assessed using a 24-hour sucrose preference test (SPT). Additionally, after 21 days of treatment, plasma corticosterone levels and hippocampal melatonin levels were assessed. Statistical analysis using either ANOVA or Kruskal-Wallis tests was then performed.&lt;strong&gt; Results: &lt;/strong&gt;The fluoxetine-Mozart group had higher SPT compared to CUMS group. However, they do not have a better result compared to other groups in terms of corticosterone and melatonin levels with values of respectively. &lt;strong&gt;Conclusion: &lt;/strong&gt;The combined therapy of fluoxetine and Mozart improved depressive-like behavior.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">348</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Lisa Pangemanan&lt;sup&gt;1*&lt;/sup&gt;, Irwanto&lt;sup&gt;2&lt;/sup&gt;, Margarita M. Maramis&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Psychiatry, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lisa Pangemanan</style></author><author><style face="normal" font="default" size="100%">Irwanto Irwanto</style></author><author><style face="normal" font="default" size="100%">Margarita M. Maramis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Antidepressant Effect of Fluoxetine and Mozart K448 Combination Therapy on Hippocampal Serotonin and BDNF Levels</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BDNF</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine</style></keyword><keyword><style  face="normal" font="default" size="100%">Hippocampus</style></keyword><keyword><style  face="normal" font="default" size="100%">Mozart</style></keyword><keyword><style  face="normal" font="default" size="100%">Serotonin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">325-328</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Despite the use of fluoxetine as a first-line therapy, some patients do not show a good therapeutic effect. Effective antidepressant therapy will reverse the low serotonin and BDNF levels found in depression. Mozart K. 448 was reported to yield a good therapeutic effect for depression. Based on findings, the combination of Mozart K. 448 and fluoxetine as a therapy for depression is very rare. Therefore, this study aimed to determine the effect of the combined therapy of fluoxetine and Mozart K. 448 on hippocampal serotonin and BDNF levels in an animal model of depression under CUMS conditions. In this study, the animal model of depression was administered three different treatments, i.e. fluoxetine, Mozart, or fluoxetine-Mozart combined therapy, respectively. Hippocampal serotonin and BDNF levels were assessed after 21 days of treatment. Statistical analysis was then carried out using T-test or Mann-Whitney test and ANOVA or Kruskal-Wallis. The fluoxetine-Mozart group has higher BDNF levels, but lower serotonin levels compared to other groups with values of 1,694±0.215 and 44,533±3,275, respectively.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">325</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Lisa Pangemanan&lt;sup&gt;1,2&lt;/sup&gt;, Irwanto Irwanto&lt;sup&gt;3,*&lt;/sup&gt;, Margarita M. Maramis&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Widya Mandala Catholic University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Psychiatry, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tácuna-Calderón Ana Lucia</style></author><author><style face="normal" font="default" size="100%">Huaccho-Rojas Juan Jesus</style></author><author><style face="normal" font="default" size="100%">Zimic-Zare Carolina</style></author><author><style face="normal" font="default" size="100%">Pante-Medina Carlos</style></author><author><style face="normal" font="default" size="100%">Salazar-Granara Alberto</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antidepressant and Antipsychotic-like Activity of the Ethanolic Extract of the Leaves of Maytenus macrocarpa</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chuchuhuasi</style></keyword><keyword><style  face="normal" font="default" size="100%">Depression</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine</style></keyword><keyword><style  face="normal" font="default" size="100%">Forced swim test</style></keyword><keyword><style  face="normal" font="default" size="100%">Haloperidol</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">November 2018</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">s33-s37</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; &lt;em&gt;Maytenus macrocarpa&lt;/em&gt; (Chuchuhuasi) is an Amazonian Peruvian traditional plant, traditionally used as anti-inflammatory, antipyretic, antihemorrhagic and antidiarrheic agent. Also, chuchuhuasi is known as a master plant, attributing to it properties in the central nervous system. In addition, depression is a disorder of the mood that cause disability to millions of people around the world. For this reason, the aim of this study was to determinate the antidepressant and antipsychotic-like activity of the ethanolic extract of Maytenus macrocarpa&lt;strong&gt;. Methods:&lt;/strong&gt; It was used the ethanolic extract of the leaves of &lt;em&gt;Maytenus macrocarpa&lt;/em&gt; (EELMM) in female mice at the experimental model of the Forced Swim Test described by Porsolt. As control, it was used distillate water, fluoxetine and haloperidol. &lt;strong&gt;Results:&lt;/strong&gt; The immobility time of the groups of EELMM has a mean of 38.26 &amp;plusmn; 21.57, 84.32 &amp;plusmn; 26.68 and 32.17 &amp;plusmn; 25.55 for the doses of 750, 1000 and 1250 mg/Kg respectively; and the immobility time had a median of 7.5 [4.07 &amp;ndash; 20.3] and 20.93 &amp;plusmn; [17.63 &amp;ndash; 23.75] for the doses of 500 mg/Kg and 1500 mg/Kg. It was seen a positive dose-response between the dose of 500 to 1000 mg/Kg (Pearson correlation of r=0.8339 and R=0.6954) and a negative dose-response between the dose of 1000 to 1500 mg/Kg. (Pearson correlation of r= -0.7590 and R= 0.5760). &lt;strong&gt;Conclusion:&lt;/strong&gt; It was demonstrated the antidepressant-like activity of the ethanolic extract of the leaves of &lt;em&gt;Maytenus macrocarpa&lt;/em&gt; with a dose of 500 mg/kg and an antipsychotic-like activity with a dose of 1000 mg/kg.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">s33</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;T&amp;aacute;cuna-Calder&amp;oacute;n Ana Lucia&lt;sup&gt;1,2,3&lt;/sup&gt;, Huaccho-Rojas Juan Jesus&lt;sup&gt;1,2,3&lt;/sup&gt;, Zimic-Zare Carolina&lt;sup&gt;1,2&lt;/sup&gt;, Pante-Medina Carlos&lt;sup&gt;1&lt;/sup&gt;, Salazar-Granara Alberto&lt;sup&gt;1,2,3*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt; 1&lt;/sup&gt;Universidad de San Martin de Porres, Facultad de Medicina Humana, Centro de Investigaci&amp;oacute;n de Medicina Tradicional y Farmacolog&amp;iacute;a, Lima, PERU.&lt;/p&gt;
&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt; 2&lt;/sup&gt;Universidad Peruana Cayetano Heredia, Facultad de Ciencias y Filosof&amp;iacute;a, Secci&amp;oacute;n Bioqu&amp;iacute;mica, Biolog&amp;iacute;a molecular y Farmacolog&amp;iacute;a, Lima, PERU.&lt;/p&gt;
&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt; 3&lt;/sup&gt;Sociedad Peruana de Farmacologia y Terap&amp;eacute;utica Experimental (SOPFARTEX), Lima, PERU.&lt;/p&gt;</style></auth-address></record></records></xml>